Table 2 28-day uncorrected and PCR-corrected efficacy estimate, by drug, by site, Madagascar, 2018

Parasitemia day 2, n (%)

1 (1)

14 (16)

8 (10)

9 (10)

Parasitemia day 3, n (%)

0

0

1 (1)

1 (1)

Early treatment failure, n (%)

0

0

1

0

Late clinical failure, n (%)

0

1 (1)

1 (1)

2 (2)

Late parasitological failure, n (%)

0

0

3 (4)

12 (14)^c

Recrudescence^a

0

0

2

2

Day 14–21

0

0

1

0

Day 22–28

0

0

1

2

Reinfection

0

1

2

11

Day 14–21

0

0

0

3

Day 22–28

0

1

2

8

Per protocol efficacy, n (% [95% CI]), uncorrected

83 (100 [96–100])

84 (99 [94–100)

79 (94 [87–98])

69 (83 [73–90])

Per protocol efficacy, n (% [95% CI]), PCR-corrected^b

83 (100 [96–100])

84 (100 [96–100])

79 (97 [90–100])

69 (95 [87–99])

Kaplan–Meier estimate of efficacy, uncorrected (% [95% CI])

100 (100–100)

99 (97–100)

95 (91–100)

83 (76–92)

Kaplan–Meier estimate of efficacy, PCR-corrected (% [95% CI])^a

100 (100–100)

100 (99–100)

98 (95–100)

95 (91–100)